Pyrisept en es it fr

Pyrisept Brand names, Pyrisept Analogs

Pyrisept Brand Names Mixture

  • No information avaliable

Pyrisept Chemical_Formula

No information avaliable

Pyrisept RX_link

Pyrisept fda sheet

Pyrisept FDA

Pyrisept msds (material safety sheet)

Pyrisept Synthesis Reference

No information avaliable

Pyrisept Molecular Weight

1431.06 g/mol

Pyrisept Melting Point

No information avaliable

Pyrisept H2O Solubility

No information avaliable

Pyrisept State


Pyrisept LogP

No information avaliable

Pyrisept Dosage Forms

Powder for solution

Pyrisept Indication

For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Pyrisept Pharmacology

Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Pyrisept Absorption

Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.

Pyrisept side effects and Toxicity

No information avaliable

Pyrisept Patient Information

Pyrisept Organisms Affected

Humans and other mammals